Voronoi Inc.

Hanmi Pharm. Co., Ltd.

Daegu-Gyeongbuk Medical Innovation Foundation

Korea Institute of Science and Technology

Korea Research Institute of Bioscience and Biotechnology

Hanmi Science Co., Ltd.

Lg Chem, Ltd

Korea Research Institute of Chemical Technology

Daegu Gyeongbuk Institute of Science and Technology

National Cancer Center

Samsung Life Public Welfare Foundation

Catholic University Industry Academic Cooperation Foundation

Voronoibio Inc.

Jung Beom Son

Hwan Geun Choi

Nam Doo Kim

Yi Kyung Ko

So Young Kim

Seock Yong Kang

Youn Ho Lee

Young Gil Ahn

Tae Bo Sim

Seungyeon Lee

Eunhwa Ko

Eun Hwa Ko

Jin-Hee Park

Hwan Mook Kim

Young Jin Ham

Young Hee Jung

Sun-Hwa Lee

Dayea Kim

Ju Hee Kang

Sun Joo Lee

Hee Sun Ryu

Jae Hyun Bae

Se In Kang

Sang Bum Kim

Sung Hwan Kim

Kwee Hyun Suh

In Hwan Bae

Maeng Sup Kim

Ji Young Song

Seung Hyun Jung

Jung Mi Hah

Eun Joo Kwak

Ho Seok Kim

Suk Kyoon Yoon

Eun Young Byun

Seung Ah Jun

Hyeon Ho Jeon

Hee Yoon Ryu

Sang Mi Han

Young Yi Lee

Eunmi Hong

Seon Ah Hwang

Woo Mi Do

In Seob Shim

Joong-heui Cho

Hong Ryul Jung

Dong-sik Park

Seung Min Lee

Dong-wook Kim

Jae Chul Lee

Eun Young Kim

Kyung Ho Yoo

Ji Yeon Song

Seung Hoon Lee

Seung Su Kim

Chang Hyun Oh

Sung Yun Cho

Young Kwan Kim

Ji Sook Kim

Do-Hyun Nam

Jae Du Ha

Dong Cho Han

Jae Yul Choi

Jong Bae Park

Ho Jong Yoon

Young Kil Chang

Woo Young Hur

Hwan Oh Kim

Byoung Mog Kwon

Dong-Sik Park

Hyun Kyoung Kim

Mi Kyoung Lee

Nam Du Kim

Chi Man Song

So Ha Lee

Han Na Cho

Seung Hye Choi

Hee Cheol Kim

Sungchan Cho

Sang Hyun Min

Seung Yeon Lee

Kyu-Sun Lee

Dong Sik Park

Tae Hun Song

Miri Choi

Shinae Kim

Joongheui Cho

Ohhwan Kwon

Heedong Park

Hyunkyoung Kim

Junggyu Park

Younho Lee

Seongho Hong

Sungwoo Lee

The present disclosure relates to a heteroaryl derivative and uses thereof. The heteroaryl derivative of the present disclosure exhibits excellent inhibitory activity against EGFR and/or HER2, and thus may be usefully employed as a therapeutic agent for EGFR- and/or HER2-related diseases.

Heteroaryl derivative compounds, and uses thereof

The present invention relates to an N-containing heteroaryl derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. The derivative exhibits high inhibitory activity against various protein kinases, particularly excellent ret proto-oncogene (RET) enzyme inhibitory ability, and has an excellent effect of inhibiting the proliferation of medullary thyroid cancer cells and lung cancer cells, which express RET fusion genes, and thus the derivative can be effectively used in the treatment of cancer, for example, medullary thyroid cancer or lung cancer, and particularly, can be effectively used in the treatment of cancer in which RET fusion genes are expressed.

N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer

The present invention relates to a 6-(isooxazolidin-2-yl)-N-phenylpyrimidin-4-amine derivative, and a pharmaceutical composition for preventing or treating cancer comprising the compound as an effective component. The compound exhibits high inhibitory activity against an epidermal growth factor receptor (EGFR) variant, or wild-type or variants of one or more of ERBB2 and ERBB4, and thus may be usefully used in the treatment of cancers in which same are expressed. In particular, the compound exhibits excellent inhibitory activity on proliferation of lung cancer cell lines, and thus can be usefully used in the treatment of lung cancer.

Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component

The present invention relates to a novel compound exhibiting enteropeptidase-inhibiting activity, a pharmaceutically acceptable salt thereof, a pharmaceutical composition for preventing and treating metabolic diseases such as obesity, diabetes mellitus or hyperlipidemia, etc. comprising the compound or pharmaceutically acceptable salt, and a method for preventing or treating metabolic disease using the above novel compound. The compound of the present invention has excellent inhibitory activity against enteropeptidase, and thus is not absorbed into the body, but are excreted outside the body. However, since not only fat but also protein are discharged together, it has few side effects such as fat stools and acts only in the gastrointestinal tract, so it has few side effects such as depression, and is very useful as a therapeutic or prophylactic drug for various metabolic diseases such as obesity, diabetes mellitus, and hyperlipidemia.

Compound exhibiting enteropeptidase inhibitory activity

The present invention relates to a novel pyrrolo-pyrimidine derivative compound, a preparation method therefor, and a pharmaceutical composition comprising the same compound as an effective ingredient for preventing or treating a protein kinase-related disease. The compound represented by Chemical Formula 1 according to the present invention, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an effective ingredient has outstanding inhibitory activity against LRRK2 kinase and against phosphorylation in the NIH-3T3 cell line, which is an LRRK2-expressing cell line, and NCC01 and 448T cell lines, which are both derived from patients with brain tumors. Verified to have inhibitory activity against various protein kinases in addition to LRRK2, the compound can find effective applications in the treatment or prevention of protein kinase-related diseases. 

Pyrrolo-pyrimidine derivative compound, preparation method therefor, and pharmaceutical composition comprising same compound as effective ingredient for preventing or treating protein kinase-related disease

The present invention relates to a pyrrolo-pyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.

Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases

The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. Also, the novel imidazopyridine derivative according to the present invention, the stereoisomer thereof, and the pharmaceutically acceptable salt thereof can effectively inhibit Src and Fyn, thereby being useful as a pharmaceutical composition for preventing or treating the Src and Fyn related diseases, and in particular, have been confirmed to be useful in diabetic nephropathy in animal model experiments. Therefore, the compound of the present invention can be effective as a pharmaceutical composition containing the same as an active ingredient for preventing or treating diabetic nephropathy.

Imidazopyridine derivative, method for preparing same, and pharmaceutical composition containing same as active ingredient for preventing or treating cancer

The present invention relates to a novel 2,3,5-substituted thiophene compound having inhibitory activity against kinases, an anticancer agent including the compound as an active ingredient, and a method for preparing the compound.

2,3,5-substituted thiophene compound as protein kinase inhibitor

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases

The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.

Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase

The present invention relates to a thieno[3,2-d]pyrimidine derivative of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, which has an excellent inhibitory activity on protein kinases, and a pharmaceutical composition comprising the same is effective in preventing or treating abnormal cell growth diseases.

Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases

Growing community of inventors

Daegu, South Korea

Jung Beom Son